ZNTL

1.3600.00%
EK

Enoch K. Kariuki

Independent Director

Dr. Enoch K. Kariuki, Pharm. D., serves as Director at Epicrispr Biotechnologies, Inc. since October 2026. He was Director of OnCusp Therapeutics, Inc. since February 2025 until July 2025 and serves as its Independent Board Advisor since July 2025. Dr. Kariuki is President at Endeavor BioMedicines, Inc. since March 2024 and was its Director until March 2024. He is Member of Investment Committee of Green D Ventures. He serves as Director at BIOCOM, Inc. since February 2021. Dr. Kariuki served as Chief Executive Officer at Lengo Therapeutics, Inc. from June 2021 until its acquisition by Blueprint Medicines Corporation in December 2021. He serves as an Independent Director at Zentalis Pharmaceuticals, Inc. since February 09, 2021. Dr. Kariuki served as an Independent Director at Imago BioSciences, Inc. since February 2021 until January 11, 2023. Dr. Kariuki served as a Chief Financial Officer at VelosBio Inc since joining the firm in July 2020 until its acquisition by Merck in December 2020. Dr. Kariuki led all finance-related and Investor Relations functions. Dr. Kariuki was Senior Vice President of Corporate Development at Synthorx, Inc since July 12, 2018, until February 2020. Dr. Kariuki led the company’s initial public offering, managed relationships with bankers, sell-side equity Analysts and Investors and led the business development process. Dr. Kariuki served as Vice President, H. I.G. BioHealth Partners of H. I.G. Capital from May 2014 to April 2018. Dr. Kariuki has significant experience in healthcare strategy, life sciences investment banking, venture capital, business development and financing. From 2014 to April 2018, Dr. Kariuki served as Vice President at H. I.G. Capital, where he focused on investments in life sciences companies. Dr. Kariuki held various roles in investment banking with Leerink Partners from 2013 to 2014 and with UBS Investment Bank from 2011 until 2013. Dr. Kariuki’s previous roles include Senior Associate at Leerink Partners and Associate Director at UBS Investment Bank. At Leerink and UBS, Dr. Kariuki advised healthcare companies on equity capital financings, mergers and acquisitions, leveraged buyouts and recapitalizations. Dr. Kariuki did a Post-Doctoral Fellowship in R&D strategy and Analytics at Bristol-Myers Squibb and was a Pharmacist at CVS Caremark. Dr. Kariuki holds an MBA from the Tuck School of Business at Dartmouth College and a Pharm. D. from Texas Southern University.

Positions